Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204918 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
A Phase 2 study of Depression, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 3
- Study locations
NCT01204918 is a Phase 2 study of Depression that has completed, run by Yale University. The registered enrollment target is 104 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01204918, a Phase 2 study of Depression, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
Conditions Studied
Interventions
- DRUG placebo
- DRUG Riluzole
Study Locations (3)
Connecticut
- Yale University, Yale Depression Research Program - New Haven
Massachusetts
- Massachussettes General Hospital, Depression Clinical and Research Center - Boston
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204918
The ClinicalTrials.gov registry entry for NCT01204918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01204918 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT01204918 about?
NCT01204918 is a clinical study titled "Efficacy and Tolerability of Riluzole in Treatment Resistant Depression". This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
What is the current status of trial NCT01204918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2011-06. Estimated completion is 2015-08.
What conditions does trial NCT01204918 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT01204918?
The interventions under investigation include: placebo (DRUG), Riluzole (DRUG).
Who is sponsoring clinical trial NCT01204918?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01204918 being conducted?
This trial has 3 study locations across Connecticut, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.